Niagen Bioscience

Home
United States
Los Angeles, CA
Niagen Bioscience

There’s a better way to age. Uncovering the potential of NAD+ with precision science.

09/01/2025

We're honored to have Dr. Vilhelm Bohr guiding Niagen® Bioscience's research efforts.

Dr. Bohr is one of the world's most published researchers in aging and neurodegenerative disease, with over 624 journal publications. For three decades, he served as Chief of the Laboratory of Molecular Genetics at the National Institute on Aging (NIH), where he made groundbreaking discoveries about DNA repair pathways, oxidative stress, aging and neurodegeneration

His pioneering work revealed critical connections between DNA damage, mitochondrial dysfunction, and age-related neurodegeneration. Dr. Bohr's research on energy homeostasis has fundamentally shaped our understanding of healthy aging.

Now maintaining his research lab at the University of Copenhagen, Dr. Bohr continues studying the benefits of NR (nicotinamide riboside) – bringing decades of expertise directly to our mission of advancing healthy aging science.

08/29/2025

In a recent interview with NBJ journalist Rick Polito, CEO Rob Fried breaks down how we built the NAD+ category from the ground up—through patient foundation-building, rigorous science, and authentic word-of-mouth. The result? Over $100M in annual sales and 38% growth in Q1 alone.

"The thing about PR and word of mouth is that people think it happens overnight. It doesn't. You build a foundation, and then the fire gets lit." - Rob Fried

Read Rick Polito's full NBJ feature at the link in our bio to learn how NAD went from biohacking early adopter circles to mainstream.

08/27/2025

We're privileged to have Nobel Laureate Dr. Roger Kornberg leading Niagen® Bioscience as Chairman of our Scientific Advisory Board.⁠
⁠
Dr. Kornberg, a Stanford Medical School professor, was awarded the 2006 Nobel Prize in Chemistry for his groundbreaking research on the molecular basis of eukaryotic transcription. His work has fundamentally advanced our understanding of how genetic information is converted into cellular function.⁠
⁠
Since founding his lab at Stanford in 1976, Dr. Kornberg has dedicated his career to reconstituting the entire transcription process using pure proteins and nucleic acids, revealing crucial structural and functional insights.⁠
⁠
Notably, Dr. Kornberg comes from a scientific dynasty—his father, the late Arthur Kornberg, was a 1959 Nobel Prize winner who was among the first researchers to investigate nicotinamide riboside over 60 years ago at NIH, establishing foundational principles of DNA replication and NAD+ synthesis.⁠
⁠
Dr. Kornberg’s research, accomplishments, and remarkable scientific legacy guide our mission today.

08/25/2025

BREAKTHROUGH: Niagen Bioscience, Inc. secures exclusive global rights as a potential Parkinson's treatment.⁠
⁠
This development signals our progression toward approved pharmaceutical applications. Backed by the Phase III NOPARK study, 400 patients across 12 sites in Norway are testing whether our NAD+ precursor can slow disease progression. Results expected by the end of 2025.⁠
⁠
Niagen is proud that its patented form of NR is leading the way in how NAD+ moves from consumer products to life-changing therapies.⁠
⁠
"This milestone underscores our commitment to translating scientific innovation into meaningful therapeutic solutions." - Rob Fried, CEO

08/21/2025

Meet Brunie Felding, Ph.D., Principal Investigator at the Scripps Research Institute, renowned breast cancer researcher, and distinguished member of our Scientific Advisory Board.⁠
⁠
As an Associate Professor in the Department of Translational Medicine at the Scripps Research Institute and Chief Scientific Officer at CureScience Brain Cancer Research Foundation, Dr. Felding is at the forefront of groundbreaking research.⁠
⁠
Her work focuses on breast cancer metastasis and NAD+ metabolism, contributing significantly to our understanding of molecular mechanisms in cancer treatment and prevention. With expertise spanning molecular medicine, genomics, and cancer biology, she brings invaluable insights to the role of NAD+ supplementation in therapeutic interventions.⁠
⁠
We're honored to have Dr. Felding's scientific expertise guiding our mission to advance NAD+ research and bring science-backed solutions to support cellular health.⁠
⁠
Learn more about the science behind Tru Niagen at www.truniagen.com

08/15/2025

Our CEO Rob Fried took the stage at Cannes Lions to share his leadership philosophy—and the took notice.

“The best way to be a trusted brand is to be a trustworthy company," says Rob, who believes in the power of consistent, purpose-driven progress with the precision science to back it up.

Read more for Rob's hot take about "future-proofing" and AI in the full article—link in our bio.

08/12/2025

Meet Dr. Rudolph Tanzi, Harvard neuroscientist, brain health innovator, and member of our Scientific Advisory Board. His extensive research has led to the co-discovery of all three early-onset Alzheimer's disease genes and has earned him recognition as one of TIME's 100 Most Influential People and membership in the National Academy of Medicine.⁠
⁠
Dr. Tanzi’s world-renowned expertise and proven success in translating genetic discoveries into therapeutic solutions bring invaluable insight to Niagen, and we are privileged to count him among our expert advisors.

08/11/2025

Rob Fried, Chief Executive Officer of Niagen Bioscience, comments on the Company's strong Q2 2025 financial performance and strategic positioning in the expanding NAD+ market. ⁠
⁠
Visit our Investor Relations site via NiagenBioscience.com to learn more. Link in bio.

08/07/2025

Niagen Bioscience recently reported total net sales of $31.1 million, with $22.7 million from Tru Niagen® up 37% and 22% respectively from the prior year quarter. Strong Q2 performance with net income of $3.6 million and raising full year outlook. 📈

https://www.businesswire.com/news/home/20250806870957/en/Niagen-Bioscience-Inc.-Reports-Second-Quarter-2025-Financial-Results-and-Increases-Full-Year-Outlook

08/04/2025

📍Boston bound!
Niagen Bioscience will be at Canaccord Genuity’s 45th Annual Growth Conference on August 12–13, 2025 at the InterContinental Boston. We’re excited to hold 1 on 1 investor meetings during the event.

📬 Schedule via your Canaccord contact.

08/01/2025

Our CEO Rob Fried recently sat down with the LA Times to discuss the science behind NAD+ supplementation and why Niagen’s scientific integrity makes for a sharp contrast to competitors with unmet label claims and inadequate quality and potency standards.

The science speaks for itself, but Fried is making sure it’s heard above the noise.

Read the full article here: https://www.latimes.com/b2b/events/cannes-lions/story/robert-fried-interview

07/30/2025

After a quarter-century of rigorous scientific research and innovation, ChromaDex evolved into Niagen Bioscience (NASDAQ: NAGE) – the leading company solely dedicated to advancing NAD+ technology through precision science.

Our clinical foundation: 35+ peer-reviewed, published human clinical trials on oral Niagen®, 300+ global research collaborations, proprietary nicotinamide riboside (NR) formulations, and a gold standard bioavailability and safety profile.

Our mission remains the same: Uncovering the potential of NAD+ with precision science. Advancing healthspan through evidence-based NAD+ enhancement, targeting the fundamental mechanisms of cellular aging.

There’s a better way to age – and science is leading the way.

Address

10900 Wilshire Boulevard Suite 600
Los Angeles, CA
90024

Website

https://linktr.ee/niagenbioscience

Alerts

Be the first to know and let us send you an email when Niagen Bioscience posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Los Angeles?